NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

NCT02611310

TerminatedN/A

Sponsor: Hoffmann-La Roche

Conditions: Metastatic Breast Cancer

Interventions: No intervention

Countries: Saudi Arabia

This is a prospective, national, multicenter, non-interventional study designed to enroll participants who have an initial diagnosis of unresectable LA/mBC made up to 6 months prior to registry enrollment. These participants will be prospectively followed for at least 5 years after study enrollment to evaluate their anti-cancer treatments. Data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrollment
* Able to comply with the study protocol

Exclusion Criteria:

None

Locations (3)

Holy Makkah, Saudi Arabia
Riyadh, Saudi Arabia
Riyadh, Saudi Arabia